Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 03, 2023 07:00 ET | Source: FibroGen, Inc.

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

- 372 IPF Patients Enrolled -- Topline Data Anticipated Mid-2024 - SAN FRANCISCO, April 03, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the completion of patient...
April 20, 2022 07:00 ET | Source: FibroGen, Inc.

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

- 356 IPF Patients Enrolled - - Topline Data Anticipated Mid-2023 - SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient...
March 11, 2016 08:00 ET | Source: FibroGen, Inc.

FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis

SAN FRANCISCO, March 11, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (FibroGen) announced today that the European Respiratory Journal (“ERJ”) published on-line a manuscript...